title: Efficacy and safety of mizoribine combined with losartan in the treatment of IgA nephropathy: a multicenter, randomized, controlled study.
abstract: BACKGROUND
  Few have tried to prove the effectiveness of mizoribine combined with losartan for adult IgA nephropathy patients in a randomized controlled trial.
  
  
  METHODS
  A multicenter, randomized, controlled, 12-month study was performed to evaluated the efficacy and safety of mizoribine combined with losartan for adult IgA nephropathy. Ninety-nine patients with primary IgA nephropathy from 8 clinical institutions were randomly assigned to the losartan group (n = 30), the mizoribine group (n = 35) or the combination (losartan+mizoribine) group (n = 34). The primary outcome was 24-hour urinary protein excretion (24 hours-UP).
  
  
  RESULTS
  There were no significant differences in baseline data among the 3 groups. In all 3 groups, 24 hours-UP after 3, 6, 9 and 12 months of treatment were significantly lower than the baseline level. The reduction in 24 hours-UP in the losartan group was observed early and reached maximum after 6 months of treatment. Twenty-four hours-UP in the mizoribine group and combination group continuously decreased during the study. Comparisons among the 3 groups showed that the losartan group was superior to the mizoribine group after 3 months of treatment, but that after 12 months of treatment, both the combination group and the mizoribine group were superior to the losartan group in the reduction of 24 hours-UP. There were no significant differences among the 3 groups in serum creatinine. No serious adverse events occurred in any of the 3 groups.
  
  
  CONCLUSIONS
  The treatment of adult IgA nephropathy with mizoribine alone, losartan alone or a combination of the 2 reduced 24 hours-UP. Mizoribine and losartan, when used in combination, complement each other's activities.
authors.affiliation: Department of Nephrology, Chinese PLA General Hospital, Beijing; China.
authors.forename: Yuansheng
authors.initials: Y
authors.lastname: Xie
authors.forename: Songmin
authors.initials: S
authors.lastname: Huang
authors.forename: Li
authors.initials: L
authors.lastname: Wang
authors.forename: Lining
authors.initials: L
authors.lastname: Miao
authors.forename: Aiping
authors.initials: A
authors.lastname: Zhang
authors.forename: Ying
authors.initials: Y
authors.lastname: Li
authors.forename: Xiongfei
authors.initials: X
authors.lastname: Wu
authors.forename: Lining
authors.initials: L
authors.lastname: Wang
authors.forename: Shuxin
authors.initials: S
authors.lastname: Liu
authors.forename: Caihua
authors.initials: C
authors.lastname: Lie
authors.forename: Pu
authors.initials: P
authors.lastname: Chen
authors.forename: Xiangmei
authors.initials: X
authors.lastname: Chen
mesh_terms: D000328:Adult; D057911:Angiotensin Receptor Antagonists / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002681:China; D003404:Creatinine / Q000097:blood; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D005922:Glomerulonephritis, IGA / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D008137:Longitudinal Studies; D019808:Losartan / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D011446:Prospective Studies; D011507:Proteinuria / Q000378:metabolism; D012263:Ribonucleosides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome; D014527:Uric Acid / Q000097:blood
chemical_list: D057911:Angiotensin Receptor Antagonists; D007166:Immunosuppressive Agents; D012263:Ribonucleosides; D014527:Uric Acid; C010052:mizoribine; D003404:Creatinine; D019808:Losartan